Sexually transmitted infections
Part of the planned inSTIcheck™ line: a rapid treponemal antibody test designed to support same-visit syphilis screening.
Target
Treponemal antibodies to T. pallidum
Sample
Fingerstick whole blood, serum or plasma
Readout
Instrument-read, logged automatically
Status
Planned · inSTIcheck™
Why it matters
Syphilis, including congenital syphilis passed from mother to baby, has risen sharply in the United States. Testing and treating in the same visit closes gaps where patients are lost to follow-up, which is why fast, reliable point-of-care results matter.
How OncoFirm will measure it
A reader-read result in minutes is intended to let clinics act while the patient is still there.
Every strip carries a fluorescent reference line of known brightness. Reading the test line against it corrects for reader and temperature drift, and the reader flags runs that did not flow correctly.
Each result is stored with the date, operator and lot, ready to share with a clinic record or laboratory system instead of being retyped by hand.
Where it's headed
01
Antibody pairs, fluorescent conjugates and strip layout are selected and tested against the target.
02
Strip, reagents and reader settings are optimized, and pilot lots are built.
03
Precision, linearity, interference and lot-to-lot consistency are measured against reference methods.
04
Performance is evaluated with clinical samples. First release is planned for research use only, followed by regulatory submissions.
Related assays
Development status. This assay and the OncoFirm platform are in development. They have not been cleared or approved by the FDA and are not available for sale. First products are planned for research use only. Descriptions reflect design goals, not demonstrated performance.
We welcome research, clinical, manufacturing and distribution partners. Tell us how this assay fits your work.